Sangui Biotech International (HAM:SBH) Total Stockholders Equity : €-0.33 Mil (As of Mar. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Sangui Biotech International Total Stockholders Equity?

Sangui Biotech International's Total Stockholders Equity for the quarter that ended in Mar. 2023 was €-0.33 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Sangui Biotech International's Book Value per Share for the quarter that ended in Mar. 2023 was €-0.00. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Sangui Biotech International's Debt-to-Equity for the quarter that ended in Mar. 2023 was -2.35.

Sangui Biotech International Total Stockholders Equity Historical Data

The historical data trend for Sangui Biotech International's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sangui Biotech International Total Stockholders Equity Chart

Sangui Biotech International Annual Data

Trend

Jun13

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Total Stockholders Equity

Get a 7-Day Free Trial

0.23

0.04

-0.07

-0.19

-0.23

Sangui Biotech International Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Total Stockholders Equity	Get a 7-Day Free Trial															-0.22	-0.23	-0.21	-0.30	-0.33

Sangui Biotech International (HAM:SBH) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Sangui Biotech International's Book Value per Share for the quarter that ended in Mar. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(-0.331	-	0)	/	209.902
	=	-0.00

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Sangui Biotech International's Debt-to-Equity for the quarter that ended in Mar. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.712	+	0.067)	/	-0.331
	=	-2.35

Sangui Biotech International Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Sangui Biotech International's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Sangui Biotech International (HAM:SBH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sangui Biotech International Inc (HAM:SBH) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

SGBI:USA

Address

Bleichenbrucke 9, Hamburg, DEU, 20354

Website

http://www.sanguibiotech.com

Sangui Biotech International Inc develops pharmaceutical, medical and cosmetic products, through its subsidiary. The company develops oxygen carriers for providing oxygen transport in humans due to acute or chronic lack of oxygen and in the case of chronic wounds. It has also developed external applications of oxygen transporters in the form of sprays for healing chronic wounds and gels and emulsions for the regeneration of the skin. The products offered are artificial oxygen carriers; Chitoskin wound pads; and haemoglobin-based wound spray technology sold under the brand name Granulox. It derives revenue from licensing fees on sales of its wound spray product.